Real-World Evaluation of Health Care Resource Utilization, Clinical Effectiveness, and Safety of Lisocabtagene Maraleucel (liso-cel) and Axicabtagene Ciloleucel (axi-cel) Administered in the Outpatient (OP) Setting for R/R Large B-cell Lymphoma (LBCL)

Key Points

• Clinical effectiveness of both liso-cel and axi-cel in outpatient settings is evident, providing valuable treatment options.
• Health care resource utilization metrics indicate efficient use of resources for large B-cell lymphoma treatment.
• Safety evaluations show that outpatient administration of liso-cel and axi-cel is feasible and well-tolerated by patients.
• Findings may inform future care models for large B-cell lymphoma, indicating potential benefits of outpatient management.